A tumor-fighting strategy: turning defeats into victories

Vita 2026 Open access

Read full text
Authors: Shibo Jiang, Guangdi Li, Xinling Wang
DOI: 10.15302/vita.2026.01.0009
Cited by: 0
References: 1

Abstract

In a study published in Vita, Tian et al. identify PNPT1 as a key immune checkpoint that suppresses antitumor immunity by degrading immunogenic mitochondrial double-stranded RNA (mt-dsRNA) and restricting its cytosolic release, thereby quelling the mt-dsRNA-mediated danger signaling. Combining PNPT1 inhibitor with BH3-mimetic agent can robustly activate the MAVS pathway, thereby overcoming immunotherapeutic resistance in solid tumors.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers interferon and immune responses Immunotherapy and Immune Responses

Publication details

Journal / source
Vita
Volume
1
Issue
1
Pages
13–13
Publication date
1 January 2026
Language
EN